Procter & Gamble Health Limited (NSE:PGHL)
India
· Delayed Price · Currency is INR 5,204.00
-36.00 (-0.69%)
Apr 24, 2025, 3:29 PM IST
Procter & Gamble Health Revenue
Procter & Gamble Health had revenue of 3.10B INR in the quarter ending December 31, 2024, a decrease of -0.06%. This brings the company's revenue in the last twelve months to 11.60B, down -6.26% year-over-year. In the fiscal year ending June 30, 2024, Procter & Gamble Health had annual revenue of 11.51B, down -6.37%.
Revenue (ttm)
11.60B
Revenue Growth
-6.26%
P/S Ratio
7.48
Revenue / Employee
8.68M
Employees
1,336
Market Cap
86.74B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2024 | 11.51B | -783.60M | -6.37% |
| Jun 30, 2023 | 12.30B | 1.15B | 10.34% |
| Jun 30, 2022 | 11.14B | 1.06B | 10.48% |
| Jun 30, 2021 | 10.09B | 1.20B | 13.52% |
| Jun 30, 2020 | 8.89B | -380.06M | -4.10% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 516.03B |
| Divi's Laboratories | 90.78B |
| Cipla | 267.20B |
| Mankind Pharma | 116.41B |
| Apollo Hospitals Enterprise | 211.46B |
| Zydus Lifesciences | 222.47B |
| Aurobindo Pharma | 309.22B |
| Alkem Laboratories | 127.57B |
Procter & Gamble Health News
- 6 months ago - P&G Health Q2 FY25: Revenue rises 2.8% YoY to Rs 313.41 crore, net profit surges 25.6% to Rs 82.33 crore - Business Upturn
- 6 months ago - Procter & Gamble Health Q2 FY25 results: Stock jumps 2% ahead of result announcement - Business Upturn